By analyzing the data of 104 patients, the authors concluded that pembrolizumab was well tolerated and demonstrated clinically meaningful antitumour activity in patients with PD-L1-positive recurrent or metastatic HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.